Tag: Obinutuzumab

1. Polatuzumab vedotin in combination with bendamustine and rituximab yielded higher complete response rates than bendamustine and rituximab alone. Evidence Rating Level: 1 (Excellent) Diffuse large B-cell lymphoma (DLBCL) is often curable, but a portion of patients are refractory to, or relapse after, treatment with the current standard of care (rituximab,...
1. Polatuzumab vedotin in combination with bendamustine and rituximab yielded higher complete response rates than bendamustine and rituximab alone. Evidence Rating Level: 1 (Excellent) Diffuse large B-cell lymphoma (DLBCL) is often curable, but a portion of patients are refractory to, or relapse after, treatment with the current standard of care (rituximab,...
1. In untreated chronic lymphocytic leukemia (CLL) patients with coexisting conditions, patients treated with venetoclax–obinutuzumab experienced greater progression-free survival compared to patients treated with chlorambucil–obinutuzumab. 2. Rates of adverse events in the two treatment groups were similar. Evidence Rating Level: 1 (Excellent)   Study Rundown: Many patients with CLL are elderly and have...
1. In untreated chronic lymphocytic leukemia (CLL) patients with coexisting conditions, patients treated with venetoclax–obinutuzumab experienced greater progression-free survival compared to patients treated with chlorambucil–obinutuzumab. 2. Rates of adverse events in the two treatment groups were similar. Evidence Rating Level: 1 (Excellent)   Study Rundown: Many patients with CLL are elderly and...
Image: PD In this section, we will highlight the key high-impact studies, updates, and analyses published in medicine during the past week. Tobacco Control and the Reduction in Smoking-Related Premature Deaths in the United States, 1964-2012 Fifty years after the initiation of tobacco control in the United States, the smoking rate has...